Triple-Drug attack before surgery shows promise for tough stomach cancers
NCT ID NCT04208347
First seen Jan 28, 2026 · Last updated May 01, 2026 · Updated 17 times
Summary
This study tests whether adding two newer drugs (apatinib and camrelizumab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced stomach or gastroesophageal junction cancer. About 580 adults with previously untreated, locally advanced disease will be randomly assigned to receive either chemotherapy plus apatinib or all three drugs. The main goals are to see if the cancer disappears completely after treatment and to measure how long patients live without the cancer returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Affiliated Hospital of Hebei University
Baoding, China
-
Affiliated Hospital of Jiangsu University
Zhenjiang, China
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
-
Cancer Hospital of the University of Chinese Academy of Sciences
Hangzhou, China
-
Changhai Hospital
Shanghai, China
-
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
-
Hainan Cancer Hospital
Haikou, China
-
Hefei Cancer Hospital, Chinese Academy of Sciences
Hefei, China
-
Henan Provincial Cancer Hospital
Zhengzhou, China
-
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, China
-
Jilin Guowen Hospital
Siping, China
-
Lanzhou University Second Hospital
Lanzhou, China
-
Liaoning Cancer Hospita & Institute
Shenyang, China
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, China
-
Sichuan Cancer Hospital & Institute
Chengdu, China
-
Sichuan Provincial People's Hospital
Chengdu, China
-
Tangdu Hospital
Xi'an, China
-
The Affiliated Hospital of Guizhou Medical University
Guiyang, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
-
Xiangya Hospital Central South University
Changsha, China
-
Yantai Yuhuangding Hospital
Yantai, China
Conditions
Explore the condition pages connected to this study.